These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 1001750)

  • 1. The metabolism of labetalol in animals and man.
    Hopkins R; Martin LE; Bland R
    Biochem Soc Trans; 1976; 4(4):726-9. PubMed ID: 1001750
    [No Abstract]   [Full Text] [Related]  

  • 2. Metabolism of labetalol by animals and man.
    Martin LE; Hopkins R; Bland R
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):695-710. PubMed ID: 990152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Affinity of labetalol for ocular melanin.
    Poynter D; Martin LE; Harrison C; Cook J
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):711-20. PubMed ID: 990153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of food on the oral and intravenous pharmacokinetics of a high clearance drug: a study with labetalol.
    Daneshmend TK; Roberts CJ
    Br J Clin Pharmacol; 1982 Jul; 14(1):73-8. PubMed ID: 7104169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of labetalol in healthy volunteers.
    Kanto J; Allonen H; Kleimola T; Mäntylä R
    Int J Clin Pharmacol Ther Toxicol; 1981 Jan; 19(1):41-4. PubMed ID: 7203731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Labetalol: bioavailability, drug plasma levels, plasma renin and catecholamines in acute and chronic treatment of resistant hypertension.
    Louis WJ; Christophidis N; Brignell M; Vijayasekaran V; McNeil J; Vajda FJ
    Aust N Z J Med; 1978 Dec; 8(6):602-9. PubMed ID: 285681
    [No Abstract]   [Full Text] [Related]  

  • 7. Decreased first-pass metabolism of labetalol in chronic liver disease.
    Homeida M; Jackson L; Roberts CJ
    Br Med J; 1978 Oct; 2(6144):1048-50. PubMed ID: 709214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-dose pharmacokinetics of labetalol in healthy young men.
    Nyberg G; Hansson R; Tietz F
    Acta Med Scand Suppl; 1982; 665():67-73. PubMed ID: 6961762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [On the acute toxicity of labetalol (AH-5158), a combined alpha-and-beta-adrenoceptor-blocking agent (author's transl)].
    Shimpo K; Fujiwara S; Katada H; Togashi H; Yokoi Y; Tanabe T
    Hokkaido Igaku Zasshi; 1978 Jan; 53(1):15-21. PubMed ID: 26632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Labetalol disposition and concentration-effect relationships during pregnancy.
    Rubin PC; Butters L; Kelman AW; Fitzsimons C; Reid JL
    Br J Clin Pharmacol; 1983 Apr; 15(4):465-70. PubMed ID: 6849783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The disposition of butriptyline in rats, dogs and man.
    Cameron BD; Chasscaud LF; Lewis JD; Taylor T
    Arzneimittelforschung; 1974 Jan; 24(1):93-6. PubMed ID: 4406119
    [No Abstract]   [Full Text] [Related]  

  • 12. Urinary metabolites of (R),(R)-labetalol.
    Alton KB; Chan TM; Pramanik BN
    Drug Metab Dispos; 1994; 22(6):866-72. PubMed ID: 7895603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Relative biological availability of labetalol after the administration of the Trandate (Allen & Hanburys) and Coreton (VULM) preparations].
    Kusala S; Janků I; Elis J; Fedelesová V; Ostrovská V; Stará D; Svobodová X; Kamenská R
    Cesk Fysiol; 1987; 36(1):78-85. PubMed ID: 3568169
    [No Abstract]   [Full Text] [Related]  

  • 14. Bioavailability of labetalol increases with age.
    Kelly JG; McGarry K; O'Malley K; O'Brien ET
    Br J Clin Pharmacol; 1982 Aug; 14(2):304-5. PubMed ID: 7104187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The determination of labetalol in plasma by high-performance liquid chromatography using fluorescence detection.
    Meredith PA; McSharry D; Elliott HL; Reid JL
    J Pharmacol Methods; 1981 Dec; 6(4):309-14. PubMed ID: 7334812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous labetalol in severe hypertension.
    Dal Palu C; Pessina AC; Semplicini A; Hlede M; Morandin F; Palatini P; Sperti G; Rossi GP
    Br J Clin Pharmacol; 1982 Jun; 13(1 Suppl):97S-99S. PubMed ID: 7093106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antihypertensive effects of labetalol administered parenterally and orally].
    Nicolaescu V; Serban-Pârâu G; Ionescu P; Nuţă M
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1984; 36(5):405-12. PubMed ID: 6151227
    [No Abstract]   [Full Text] [Related]  

  • 18. Use of labetalol and methyldopa in pregnancy-induced hypertension.
    Lamming GD; Symonds EB
    Br J Clin Pharmacol; 1979; 8(Suppl 2):217S-222S. PubMed ID: 526404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cimetidine and bioavailability of labetalol.
    Daneshmend TK; Roberts CJ
    Lancet; 1981 Mar; 1(8219):565. PubMed ID: 6111669
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical and pharmacokinetic studies on the alpha- and beta-blocking drug labetalol.
    Kanto J; Allonen H; Lehtonen A; Mäntylä R; Pakkanen A
    Ther Drug Monit; 1980; 2(2):145. PubMed ID: 7052285
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.